US2011217273A1PendingUtilityA1

Composition for Preventing or Treating AIDS Containing Plant Stem Cell Line Derived from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng as Active Ingredient

Assignee: UNHWA CORPPriority: Sep 30, 2008Filed: Sep 30, 2009Published: Sep 8, 2011
Est. expirySep 30, 2028(~2.2 yrs left)· nominal 20-yr term from priority
A61P 37/00A61P 37/04A61P 31/18A61P 31/12A23L 33/10A23L 33/105A23V 2002/00C12N 5/04A61K 36/258A01H 4/005
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a composition for preventing or treating acquired immunodeficiency syndrome (AIDS), comprising one or more of the following: a homogenous cell line, and a lysate, an extract and a culture thereof as an active ingredient. The homogenous cell line, the lysate, the extract and the culture thereof, which are derived from a natural product, minimize adverse side effects of prior therapeutic agents and safe for the human body. Further, they effectively increase the count of T cells such as CD4+ T cells and decrease the number of HIVs, thereby preventing opportunistic infection, dysneuria, and neoplasia caused by immune incompetence, and ultimately the risk of death. Therefore, they are useful in preventing and treating AIDS, and relieving symptoms of AIDS.

Claims

exact text as granted — not AI-modified
1 . A composition for preventing or treating acquired immunodeficiency syndrome (AIDS), comprising one or more of the following: a cell line, and a lysate, an extract and a culture thereof, wherein the cell line is derived from the cambium of Panax ginseng and has the following characteristics:
 (a) it is in an innately undifferentiated state;   (b) it is a homogeneous cell line; and   (c) it is morphologically characterized by multiple vacuoles.   
     
     
         2 . The composition of  claim 1 , wherein the cell line further has the following characteristics:
 (a) it is present as single cell level during a suspension culture;   (b) it has a lower sensitivity to shear stress in a bioreactor, compared to cell lines derived from tissues other than the cambium of Panax ginseng; and   (c) its growth rate is higher than those of cell lines derived from tissues other than the cambium of Panax ginseng and is cultured stably.   
     
     
         3 . The composition of  claim 1 , wherein the cell line is obtained by using an isolation method comprising the steps of:
 (a) obtaining a Panax ginseng cambium-containing tissue;   (b) culturing the cambium-containing tissue in a medium supplemented with IAA (indole-3-acetic acid) or IBA (indole-3-butyric acid) to induce a cell line derived from the cambium, wherein an osmotic stress is applied to the cambium-containing tissue before, during, or after the culture; and   (c) collecting the induced, cambium-derived cell line.   
     
     
         4 . The composition of  claim 3 , wherein step (c) is performed by proliferating the induced cambium-derived cell line in a medium which contains one or more of 2,4-D(2,4-dichlorophenoxyacetic acid), picloram and IBA, and then collecting the cambium-derived cells. 
     
     
         5 . The composition of  claim 1 , wherein the extract is obtained by using a solvent selected from the group consisting of distilled water, lower alcohol, acetone, dimethyl sulfoxide and a mixture thereof. 
     
     
         6 . A functional food for preventing or ameliorating AIDS, comprising one or more of the following: a cell line, and a lysate, an extract and a culture thereof, wherein the cell line is derived from the cambium of Panax ginseng and has the following characteristics:
 (a) it is in an innately undifferentiated state;   (b) it is a homogeneous cell line; and   (c) it is morphologically characterized by multiple vacuoles.   
     
     
         7 . The functional food of  claim 6 , wherein the cell line further has the following characterstics:
 (a) it is present as single cell level during a suspension culture;   (b) it has a lower sensitivity to shear stress in a bioreactor, compared to cell lines derived from tissues other than the cambium of Panax ginseng; and   (c) its growth rate is higher than those of cell lines derived from tissues other than the cambium of Panax ginseng and is cultured stably.   
     
     
         8 . The functional food of  claim 6 , wherein the cell line is obtained by using an isolation method comprising the steps of:
 (a) obtaining a Panax ginseng cambium-containing tissue;   (b) culturing the cambium-containing tissue in a medium supplemented with IAA or IBA to induce a cell line derived from the cambium, wherein an osmotic stress is applied to the cambium-containing tissue before, during, or after the culture; and   (c) collecting the induced, cambium-derived cell line.   
     
     
         9 . The functional food of  claim 8 , wherein step (c) is performed by proliferating the induced cambium-derived cell line in a medium which contains one or more of 2,4-D, picloram and IBA, and then collecting the cambium-derived cells. 
     
     
         10 . An immune enhancing agent for increasing T cells, comprising one or more of the following: a cell line, and a lysate, an extract and a culture thereof, wherein the cell line is derived from the cambium of Panax ginseng and has the following characteristics:
 (a) it is in an innately undifferentiated state;   (b) it is a homogeneous cell line; and   (c) it is morphologically characterized by multiple vacuoles.   
     
     
         11 . The immune enhancing agent of  claim 10 , wherein the cell line is obtained by using an isolation method comprising the steps of:
 (a) obtaining a Panax ginseng cambium-containing tissue;   (b) culturing the cambium-containing tissue in a medium supplemented with IAA or IBA to induce a cell line derived from the cambium, wherein an osmotic stress is applied to the cambium-containing tissue before, during, or after the culture; and   (c) collecting the induced, cambium-derived cell line.   
     
     
         12 . The immune enhancing agent of  claim 11 , wherein step (c) is performed by proliferating the induced cambium-derived cell line in a medium which contains one or more of 2,4-D, picloram and IBA, and then collecting the cambium-derived cells.

Join the waitlist — get patent alerts

Track US2011217273A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.